Literature DB >> 314324

Clinical staging and immunological findings in chronic lymphocytic leukemia.

R Foa, D Catovsky, M Brozovic, G Marsh, T Ooyirilangkumaran, M Cherchi, D A Galton.   

Abstract

Several immunological markers were tested in 52 untreated cases of chronic lymphocyte leukemia (CLL) to see whether their frequency differed according to the clinical stage in Rai's system. The leukemic cells in all cases had B-cell features as shown by monoclonal immunoglobulins on the cell surface (SmIg) and/or a high percentage of mouse RBC (M)-rosettes. Of the two B-cell markers, the M-rosette test was the more consistently positive. The frequency of these markers did not correlate with clinical staging. The percentage of T-lymphocytes, low in all cases, was found to correlate inversely with the lymphocyte counts, which were higher in advanced stages. The absolute number of T-lymphocytes was above normal in most cases, but did not relat to staging. At least one of the serum Ig, most commonly IgA, was decreased in 87% of cases. Low Ig were slightly less common in Stages 0-I than in advanced stages (II-IV). The above features were also examined in two groups of CLL patients: with stable (9) or progressive (16) disease. The only difference observed between the two groups was that surface IgM only was present in 1 of the 9 stable cases as compared to 9 of the 16 progressive ones. Our findings do not support the suggestions that surface IgM is a feature of a benign form of CLL or that the absolute number of T-lymphocytes correlates with prognosis.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 314324     DOI: 10.1002/1097-0142(197908)44:2<483::aid-cncr2820440217>3.0.co;2-z

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  12 in total

Review 1.  Immune deficiencies in chronic lymphocytic leukemia and multiple myeloma.

Authors:  A Winkelstein; P S Jordan
Journal:  Clin Rev Allergy       Date:  1992 Spring-Summer

2.  Hypogammaglobulinemia in newly diagnosed chronic lymphocytic leukemia: Natural history, clinical correlates, and outcomes.

Authors:  Sameer A Parikh; Jose F Leis; Kari G Chaffee; Timothy G Call; Curtis A Hanson; Wei Ding; Asher A Chanan-Khan; Deborah Bowen; Michael Conte; Susan Schwager; Susan L Slager; Daniel L Van Dyke; Diane F Jelinek; Neil E Kay; Tait D Shanafelt
Journal:  Cancer       Date:  2015-04-30       Impact factor: 6.860

3.  Impaired mitogen responses of the non-leukaemic B cells from patients with chronic lymphocytic leukaemia.

Authors:  A Morgan; J Eaves; J W Mockford; V Malkovska
Journal:  Clin Exp Immunol       Date:  1989-08       Impact factor: 4.330

4.  Flow cytometric analysis of T-lymphocyte subpopulations in B-cell chronic lymphocytic leukemia: correlation with clinical stage.

Authors:  M L Hautekeete; R F De Bock; D R Van Bockstaele; G C Colpin; Z N Berneman; M E Peetermans
Journal:  Blut       Date:  1987-11

5.  Combined immunodeficiency preceding chronic lymphocytic leukemia.

Authors:  J W Lenders; B E de Pauw; M J Bogman; C Haanen
Journal:  Blut       Date:  1984-03

6.  Imbalance of T cell subpopulations in patients with chronic lymphocytic leukaemia of the B cell type.

Authors:  F Herrmann; A Lochner; H Philippen; B Jauer; H Rühl
Journal:  Clin Exp Immunol       Date:  1982-07       Impact factor: 4.330

7.  Routine flow cytometric diagnosis of lymphoproliferative disorders.

Authors:  I G Barr; B H Toh
Journal:  J Clin Immunol       Date:  1983-04       Impact factor: 8.317

8.  Spontaneous mouse erythrocyte-rosette formation in chronic lymphocytic leukaemia.

Authors:  E Kuhlein; G Laurent; F Rigal; G Delsol; J Pris; J Ducos
Journal:  Clin Exp Immunol       Date:  1982-02       Impact factor: 4.330

9.  Mouse rosette positive B cells fail to synthesize immunoglobulin following incubation with pokeweed mitogen.

Authors:  F R Davey; A S Kurec; H V Lamberson
Journal:  Clin Exp Immunol       Date:  1983-12       Impact factor: 4.330

10.  Characterization of chronic lymphocytic leukemia (CLL) cells with low density of surface membrane bound immunoglobulins (smIg).

Authors:  E Kimby; B Axelsson; M Björkholm; J Gordon; G Holm; H Mellstedt
Journal:  Med Oncol Tumor Pharmacother       Date:  1985
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.